Chaini Konwar

Chaini Konwar

Auto-generated profile, based on publicly available information

Chaini Konwar

Edwin S. H. Leong Centre for Healthy Aging, Faculty of Medicine, University of British Columbia

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 July 2025 in Life Science Alliance
Verified
Journal Article
Open access
BZBeryl C Zhuang
Beryl C Zhuang
MJMarcia Smiti Jude
Marcia Smiti Jude
CKChaini Konwar
Chaini Konwar
NYNatan Yusupov
Natan Yusupov
CRCalen P Ryan
Calen P Ryan
MKMichael Kobor
Michael Kobor
The recently launched Illumina Infinium MethylationEPIC v2.0 (EPICv2), successor of MethylationEPIC v1.0 (EPICv1), retains most of the probes in EPICv1, while expanding coverage of regulatory elements. The concordance between the two EPIC versions in DNA methylation–based tools has not yet been investigated. To address this, DNA methylation was profiled on both versions using matched blood samples across four cohorts spanning early to late adulthood. High concordance between versions at the array level but variable agreement at the individual probe level was noted. A significant contribution of the EPIC version to DNA methylation variation was observed, though it was to a smaller extent compared with sample relatedness and cell-type composition. Modest but significant differences in DNA methylation–based estimates between versions were observed, irrespective of the data preprocessing method used. Adjustments for EPIC version or calculation of estimates separately for each version largely mitigated these version-specific discordances. This work emphasizes the importance of accounting for EPIC version differences in research scenarios, especially in meta-analyses and longitudinal studies that require data harmonization across versions.

3 July 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
BZBeryl C. Zhuang
Beryl C. Zhuang
MJMarcia Smiti Jude
Marcia Smiti Jude
CKChaini Konwar
Chaini Konwar
NYNatan Yusupov
Natan Yusupov
CRCalen P. Ryan
Calen P. Ryan
MKMichael Kobor
Michael Kobor
Background The recently launched DNA methylation profiling platform, Illumina MethylationEPIC BeadChip Infinium microarray v2.0 (EPICv2), is highly correlated with measurements obtained from its predecessor MethylationEPIC BeadChip Infinium microarray v1.0 (EPICv1). However, the concordance between the two versions in the context of DNA methylation-based tools, including cell type deconvolution algorithms, epigenetic clocks, and inflammation and lifestyle biomarkers has not yet been investigated. Findings We profiled DNA methylation on both EPIC versions using matched venous blood samples from individuals spanning early to late adulthood across three cohorts. On combining the DNA methylomes of the cohorts, we observed that samples primarily clustered by the EPIC version they were measured on. Within each cohort, when we calculated cell type proportions, epigenetic age acceleration (EAA), rate of aging estimates, and biomarker scores for the matched samples on each version, we noted significant differences between EPICv1 and EPICv2 in the majority of these estimates. These differences were not significant, however, when estimates were adjusted for EPIC version or when EAAs were calculated separately for each EPIC version. Conclusions Our findings indicate that EPIC version differences predominantly explain DNA methylation variation and influence estimates of DNA methylation-based tools, and therefore we recommend caution when combining cohorts run on different versions. We demonstrate the importance of calculating DNA methylation-based estimates separately for each EPIC version or accounting for EPIC version either as a covariate in statistical models or by using version correction algorithms.

22 June 2022 in medRxiv
Verified
Preprint
Open access
PDF file
AIAmy Inkster
Amy Inkster
CKChaini Konwar
Chaini Konwar
MPMaria S. Peñaherrera
Maria S. Peñaherrera
UBUrsula Brain
Ursula Brain
AKAlmas Khan
Almas Khan
WRWendy Robinson
Wendy Robinson
Background: Selective serotonin reuptake inhibitors (SSRIs) for treatment of prenatal maternal depression have been associated with neonatal neurobehavioral disturbances, though the molecular mechanisms remain poorly understood. In utero exposure to SSRIs may affect DNA methylation (DNAme) in the human placenta, an epigenetic mark that is established during development and is associated with gene expression. Methods: Chorionic villus samples from 64 human placentas were profiled with the Illumina MethylationEPIC BeadChip; clinical assessments of maternal mood and SSRI treatment records were collected at multiple time points during pregnancy. Case distribution was 20 SSRI-exposed cases and 44 SSRI non-exposed cases. Maternal depression was defined using a mean maternal Hamilton Depression score >8 to indicate symptomatic depressed mood (“maternally-depressed”), and we further classified cases into SSRI-exposed, maternally-depressed (n=14); SSRI-exposed, not maternally-depressed (n=6); SSRI non-exposed, maternally-depressed (n=20); and SSRI non-exposed, not maternally-depressed (n=24). For replication, Illumina 450K DNAme profiles were obtained from 34 additional cases from an independent cohort (n=17 SSRI-exposed, n=17 SSRI non-exposed). Results: No CpGs were differentially methylated at FDR < 0.05 comparing SSRI-exposed to non-exposed placentas, in a model adjusted for mean maternal Hamilton Depression score, or in a model restricted to maternally-depressed cases with and without SSRI exposure. However, at a relaxed threshold of FDR < 0.25, five CpGs were differentially methylated (|Δβ| > 0.03) by SSRI exposure status. Four were covered by the replication cohort measured by the 450K array, but none replicated. No CpGs were differentially methylated (FDR < 0.25) comparing maternally depressed to not depressed cases. In sex-stratified analyses for SSRI-exposed versus non-exposed cases (females n=31; males n=33), three additional CpGs in females, but none in males, were differentially methylated at the relaxed FDR < 0.25 cut-off. Conclusions: We did not observe large-scale alterations of DNAme in placentas exposed to maternal SSRI treatment compared to placentas with no SSRI exposure. We also found no evidence for altered DNAme in maternal depression-exposed versus depression non-exposed placentas. This novel work in a prospectively-recruited cohort with clinician-ascertained SSRI exposure and mood assessments would benefit from future replication.


24 April 2025 in bioRxiv
Verified
Preprint
Open access
MFMaggie P. Fu
Maggie P. Fu
KEKarlie Edwards
Karlie Edwards
ENErick I. Navarro-Delgado
Erick I. Navarro-Delgado
SMSarah M. Merrill
Sarah M. Merrill
NKNegusse Tadesse Kitaba
Negusse Tadesse Kitaba
MKMichael Kobor
Michael Kobor
Prospective birth cohorts offer the potential to interrogate the relation between early life environment and embedded biological processes such as DNA methylation (DNAme). These association studies are frequently conducted in the context of blood, a heterogeneous tissue composed of diverse cell types. Accounting for this cellular heterogeneity across samples is essential, as it is a main contributor to inter-individual DNAme variation. Integrated blood cell deconvolution of pediatric and longitudinal birth cohorts poses a major challenge, as existing methods fail to account for the distinct cell population shift between birth and adolescence. In this paper, we critically evaluated the reference-based deconvolution procedure and optimized its prediction accuracy for longitudinal birth cohorts using DNAme data from the Canadian Healthy Infant Longitudinal Development (CHILD) cohort. The optimized algorithm, CellsPickMe , integrates cord and adult references and picks DNA me features for each population of cells with machine learning algorithms. It demonstrated improved deconvolution accuracy in cord, pediatric, and adult blood samples compared to existing benchmark methods. CellsPickMe supports blood cell deconvolution across early developmental periods under a single framework, enabling cross-time-point integration of longitudinal DNAme studies. Given the increased resolution of cell populations predicted by CellsPickMe , this R package empowers researchers to explore immune system dynamics using DNAme data in population studies across the life course.

13 May 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
ENErick I. Navarro-Delgado
Erick I. Navarro-Delgado
DCDarina Czamara
Darina Czamara
KEKarlie Edwards
Karlie Edwards
MFMaggie P. Fu
Maggie P. Fu
SMSarah M. Merrill
Sarah M. Merrill
MKMichael Kobor
Michael Kobor
DNA methylation (DNAme) is the most commonly studied epigenetic mark in human populations. DNAme has gained attention in the Developmental Origins of Health and Disease field due to its gene expression regulation and potential long-term stability. Genetic variation and environmental exposures are amongst the main factors influencing inter-individual DNAme variability. However, the proportion and genomic distribution of their individual, additive and interactive effects on the DNA methylome remains unclear. Here, we introduce RAMEN, a Findable, Accessible, Interoperable, and Reusable (FAIR) framework tailored for DNAme microarrays. Using machine learning and statistical techniques, RAMEN models and dissects gene-environment contributions to genome-wide Variably Methylated Regions (VMRs), while controlling for spurious associations. To comprehensively test the power of RAMEN, we analyzed and characterized VMRs from cord blood samples from two independent cohorts (CHILD and PREDO; overall n=1,662). We identified genetics as a consistent key contributor to DNAme variability, usually in additive and interactive combinations with the environment, with genetic terms explaining the largest proportion of DNAme variance, compared to environmental and interaction terms. Operationalizing RAMEN as an R package to conduct scalable genome-exposome contribution analyses, our results highlighted the importance of genetic variation in sculpting DNAme patterns in early life.